<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782275</url>
  </required_header>
  <id_info>
    <org_study_id>08-184</org_study_id>
    <nct_id>NCT00782275</nct_id>
  </id_info>
  <brief_title>Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma</brief_title>
  <official_title>A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm phase II trial evaluating the combination of avastin and temsirolimus in
      patients with metastatic renal cell cancer (RCC) including both histologically confirmed
      clear cell (cc) or non-clear cell (ncc) subtypes. Patients must have experienced disease
      progression or intolerable toxicity with a vascular endothelial growth factor (VEGF)-targeted
      tyrosine kinase inhibitor (TKI) (e.g. sorafenib, sunitinib, pazopanib). Only 2 prior VEGF
      therapies are allowed. The purpose of this research study is to evaluate efficacy of the
      combination against an historical control. Temsirolimus has been approved by the Food and
      Drug Administration (FDA) in the treatment of renal cell carcinoma. Avastin has been approved
      by the FDA for other types of cancers but not renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Avastin, a humanized IgG1 monoclonal antibody (MAb), inhibits vascular endothelial growth
      factor (VEGF). VEGF is one of the most potent and specific proangiogenic factors and has been
      identified as a crucial regulator of both normal and pathological angiogenesis. Temsirolimus
      specifically inhibits the mammalian target of rapamycin (mTOR), a highly conserved
      serine/threonine kinase which regulates cell growth and metabolism in response to
      environmental factors. The combination avastin and temsirolimus has already demonstrated
      efficacy in the phase I setting

      STATISTICAL CONSIDERATIONS:

      The primary endpoint is 4-month PFS. The null and alternative hypotheses are 50% vs. 70%.
      Assuming 2 ineligible patients, the target sample size is 41 patients (39 eligible patients).
      The probability of concluding that the treatment is effective was &gt;0.90 if the true rate is
      at least 70%. The probability of concluding that the treatment is effective was â‰¤ 0.10 if the
      true rate was 50% or less. If 24 or more patients are alive and progression-free at 4 months,
      then this regimen would be considered for further study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-month Progression-Free Survival Rate</measure>
    <time_frame>Disease evaluations occurred every 8 weeks (+/- 1 wk) on treatment. Relevant for this endpoint was disease status at 4 months.</time_frame>
    <description>4-month progression-free survival rate was defined as the percentage of participants absent death or progression based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST) before 4 months. Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Disease evaluations occurred every 8 weeks (+/- 1 wk) on treatment; Treatment continued until disease progression or unacceptable toxicity. Median (range) of treatment duration for this study cohort was 5 cycles (1-39) [1 cycle=28days].</time_frame>
    <description>Objective response (OR) rate is the percentage of participants achieving partial response (PR) or complete response (CR) based on RECIST 1.0 criteria on treatment. Per RECIST 1.0 for target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no fewer than 4 weeks after the response criteria are first met. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Median follow-up for survival in this study cohort is 56 months.</time_frame>
    <description>Overall survival (OS) is defined from the date of registration to date of death, or censored at the date the participant was last known alive. OS is estimated based on the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab and temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28-days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>bevacizumab and temsirolimus</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <arm_group_label>bevacizumab and temsirolimus</arm_group_label>
    <other_name>torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed renal cell carcinoma in either primary or metastatic lesions.
             Non-clear histology will be allowed.

          -  Disease progression on a VEGF-targeted tyrosine kinase inhibitor as the most recent
             therapy or have experienced intolerable toxicity so as require discontinuation. Only
             one prior VEGF-targeted tyrosine kinase inhibitor.

          -  Must be off of VEGF-targeted tyrosine kinase inhibitor for 2 weeks or greater.

          -  One measurable lesion which is not curable by standard radiation therapy or surgery.

          -  The enrolling site must agree to obtain paraffin-embedded tumor blocks or at least 10
             unstained, paraffin-embedded slides for submission for correlative studies.

          -  18 years of age or older

          -  ECOG Performance Status of 0 or 1

          -  Baseline laboratory values as outlined in the protocol

          -  Life expectancy of greater than 3 months

          -  No prior malignancy diagnosed within the past three years, other than superficial
             basal cell and superficial squamous cell, or carcinoma in situ of the cervix.

        Exclusion Criteria:

          -  Known CNS disease, except for treated brain metastases

          -  Previously treated with avastin or mTOR inhibitors

          -  Other then VEFG-targeted TKI, patients may only have had prior immunotherapy or
             chemotherapy for stage IV disease

          -  History of allergic reaction to Chinese hamster ovary cell products, other recombinant
             antibodies, or compounds of similar chemical or biologic composition to avastin or
             temsirolimus

          -  History of bleeding diathesis or coagulopathy. Therapeutic anticoagulants are allowed

          -  Patients with clinically significant cardiovascular disease

          -  Patients receiving enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer
             such as rifampin or St. John's wort

          -  No serious non-healing wound, ulcer or bone fracture

          -  No uncontrolled intercurrent illness including , but not limited to, ongoing active
             infection requiring parental antibiotics or psychiatric illness/social situations that
             would limit compliance with study requirements

          -  HIV-positive receiving combination anti-retroviral therapy

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study enrollment or anticipation of need for major surgical procedure during
             the course of the study

          -  Core biopsy or other minor surgical procedure, excluding placement of vascular access
             device, within 7 days prior to enrollment on study

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to study enrollment

          -  Known hypersensitivity to any component of avastin or temsirolimus

          -  Life expectancy of less than 12 weeks

          -  History of hemoptysis within 1 month prior to day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David McDermott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univeristy Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, Choueiri TK. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 Aug;14(4):304-313.e6. doi: 10.1016/j.clgc.2016.02.007. Epub 2016 Feb 23.</citation>
    <PMID>27036973</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>February 1, 2017</results_first_submitted>
  <results_first_submitted_qc>November 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 20, 2017</results_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>David F. McDermott, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>avastin</keyword>
  <keyword>temsirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between April 2009 and May 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Temsirolimus</title>
          <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28 days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Prior VEGFR Response Evaluable</title>
              <participants_list>
                <participants group_id="P1" count="39">One patient was unevaluable and therefore excluded from related subgroup analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Since treatment duration was not fixed, patients were not considered to have completed treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not started treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis dataset is comprised of all treated patients as opposed to enrolled patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Temsirolimus</title>
          <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28 days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="32" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary VEGF Refractory Status</title>
          <description>Primary VEGF refractory status was based on the prior therapy form; patients were considered refractory if response on prior therapy was progressive disease OR prior therapy duration was &lt; 3 months and patient experienced progression at the end of therapy.</description>
          <population>One patient did not have enough data to determine VEGF-refractory status.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>VEGF Refractory-No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF Refractory-Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MSKCC Risk Category</title>
          <description>The Memorial Sloan Kettering Cancer Center (MSKCC) risk score is based on the sum of positive answers to the following criteria: 1) time from the earliest of initial or metastatic diagnosis to first prior treatment &lt; 1 year; 2) Karnofsky Performance Score &lt; 80%; 3) HgB &lt; LLN; 4) Corrected Calcium &gt; 10 mg/dL; and 5) NLDH&gt; 1.5xULN. Patients were further classified into risk groups based on the score of 0=Favorable, 1-2=Intermediate and 3-5=Poor Risk. (Motzer et al. Cancer 2008; 113)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Favorable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermediate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>4-month Progression-Free Survival Rate</title>
        <description>4-month progression-free survival rate was defined as the percentage of participants absent death or progression based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST) before 4 months. Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.</description>
        <time_frame>Disease evaluations occurred every 8 weeks (+/- 1 wk) on treatment. Relevant for this endpoint was disease status at 4 months.</time_frame>
        <population>The analysis dataset is comprised of all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Temsirolimus</title>
            <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28 days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
          </group>
        </group_list>
        <measure>
          <title>4-month Progression-Free Survival Rate</title>
          <description>4-month progression-free survival rate was defined as the percentage of participants absent death or progression based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST) before 4 months. Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.</description>
          <population>The analysis dataset is comprised of all treated participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="50.8" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The regimen was evaluated against an historical control with null and alternative 4-month PFS rates of 50% and 70%, respectively. With the final sample size of 40 eligible patients and using the same operating characteristics (alpha and beta 10%), the decision rule changes such that if 25 or more patients of 40 are alive and progression-free at 4 months then this regimen is considered promising.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>exact binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>Objective response (OR) rate is the percentage of participants achieving partial response (PR) or complete response (CR) based on RECIST 1.0 criteria on treatment. Per RECIST 1.0 for target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no fewer than 4 weeks after the response criteria are first met. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.</description>
        <time_frame>Disease evaluations occurred every 8 weeks (+/- 1 wk) on treatment; Treatment continued until disease progression or unacceptable toxicity. Median (range) of treatment duration for this study cohort was 5 cycles (1-39) [1 cycle=28days].</time_frame>
        <population>The analysis dataset is comprised of all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Temsirolimus</title>
            <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28 days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective response (OR) rate is the percentage of participants achieving partial response (PR) or complete response (CR) based on RECIST 1.0 criteria on treatment. Per RECIST 1.0 for target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no fewer than 4 weeks after the response criteria are first met. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.</description>
          <population>The analysis dataset is comprised of all treated participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="8.5" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) is defined from the date of registration to date of death, or censored at the date the participant was last known alive. OS is estimated based on the Kaplan-Meier method.</description>
        <time_frame>Median follow-up for survival in this study cohort is 56 months.</time_frame>
        <population>The analysis dataset is comprised of all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Temsirolimus</title>
            <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28 days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) is defined from the date of registration to date of death, or censored at the date the participant was last known alive. OS is estimated based on the Kaplan-Meier method.</description>
          <population>The analysis dataset is comprised of all treated participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="7.7" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Treatment duration in cycles was a median (range) of 5 (1-39) which parallels time in months given the 28 day cycle duration.</time_frame>
      <desc>Maximum grade toxicity by type was first calculated including events only with temsirolimus and/or bevacizumab treatment-attribution of possibly, probably or definitely. Serious AEs were defined as grade 3 or higher events per CTCAEv3. Other AEs were defined as grades 1 or 2 events per CTCAEv3. No further data is available to specify classification of 'other' beyond the general term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Temsirolimus</title>
          <description>bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
1 cycle=28 days
There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fistula, Esophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lower GI, hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Syndromes-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/ unk ANC skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound - non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vascular access,Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haptoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary/ Upper Respiratory- other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash/ desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Thrombosis/ thrombus/ embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Arrhythmia-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Distention/bloating, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oral cavity, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rectum, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdomen, pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anus, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dental/teeth/peridontal, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oral cavity, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oral gums, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constitutional, other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema head and neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema trunk/genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest/thoracic pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Face, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut, sinus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC nerve-peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nonneuropathic generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Back, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest wall, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Joint, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscle, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinus, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Renal/GU-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleura, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Throat/pharynx/larynx, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Scalp, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David F. McDermott MD PhD</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-632-9262</phone>
      <email>dmcdermo@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

